상세검색
최근 검색어 삭제
다국어입력
즐겨찾기0
논문
 SCOPUS  SCIE  KCI등재 학술저널

Cyclophilin A as a New Therapeutic Target for Hepatitis C Virus- induced Hepatocellular Carcinoma

Cyclophilin A as a New Therapeutic Target for Hepatitis C Virus- induced Hepatocellular Carcinoma

  • 이용수 2
커버이미지 없음

초록

Hepatocellular carcinoma (HCC) related to hepatitis B virus (HBV) and hepatitis C virus (HCV) infections is thought to account for more than 80% of primary liver cancers. Both HBV and HCV can establish chronic liver inflammatory infections, altering hepatocyte and liver physiology with potential liver disease progression and HCC development. Cyclophilin A (CypA) has been identified as an essential host factor for the HCV replication by physically interacting with the HCV non structural protein NS5A that in turn interacts with RNA-dependent RNA polymerase NS5B. CypA, a cytosolic binding protein of the immunosuppressive drug cyclosporine A, is overexpressed in many cancer types and often associated with malignant transformation. Therefore, CypA can be a good target for molecular cancer therapy. Because of antiviral activity, the CypA inhibitors have been tested for the treatment of chronic hepatitis C. Nonimmunosuppressive Cyp inhibitors such as NIM811, SCY-635, and Alisporivir have attracted more interests for appropriating CypA for antiviral chemotherapeutic target on HCV infection. This review describes CypA inhibitors as a potential HCC treatment tool that is contrived by their obstructing chronic HCV infection and summarizes roles of CypA in cancer development.

목차

등록된 목차 정보가 없습니다.

참고문헌 (0)

등록된 참고문헌 정보가 없습니다.

로딩중